Guard Therapeutics International AB (publ) (STO: GUARD)
Sweden
· Delayed Price · Currency is SEK 20.20
-0.60 (-2.88%)
Nov 18, 2024, 4:38 PM CET
GUARD Company Description
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden.
It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues.
The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019.
Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Guard Therapeutics International AB (publ)
| Country | Sweden |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Tobias Agervald |
Contact Details
Address: Nybrogatan 34, 2 tr Stockholm, 114 39 Sweden | |
| Phone | 46 86 70 65 51 |
| Website | guardtherapeutics.com |
Stock Details
| Ticker Symbol | GUARD |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0009973357 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tobias Larsson Agervald | Chief Executive Officer |
| Karin Botha | Chief Financial Officer |
| Magnus Gram | C.S.O |
| Peter Gilmour Ph.D. | Head of Preclinical Science |
| Sara Thuresson | Head of Clinical Operations |
| Dr. Michael Reusch | Chief Medical Officer |
| Torbjorn Larsson | Head of Chemistry, Manufacturing and Controls |